The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

August 14, 2020

Kami J. Maddocks, MD, discusses the clinical implications of the approval of tafasitamab and lenalidomide in relapsed/refractory DLBCL, as well as remaining challenges that future research efforts should address.

August 11, 2020

Jennifer Woyach, MD, discusses ​the role of chemoimmunotherapy in chronic lymphocytic leukemia.

June 24, 2020

David O'Malley, MD, discusses the utility of mirvetuximab soravtansine in ovarian cancer.

June 11, 2020

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

June 10, 2020

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

May 28, 2020

Gregory A. Otterson, MD, discusses data examining immunotherapy alone versus in combination in non–small cell lung cancer.

May 27, 2020

Jonathan E. Brammer, MD, discusses data that have been reported with inotuzumab ozogamicin (Besponsa) in acute lymphoblastic leukemia (ALL).

May 27, 2020

Alice S. Mims, MD, discusses the Beat AML Master Trial in acute myeloid leukemia (AML).

May 19, 2020

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

May 19, 2020

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

May 05, 2020

Ritu Salani, MD, discusses the evolving role of biomarker development and testing in cervical cancer.

May 05, 2020

David P. Carbone, MD, PhD, discusses a study evaluating acquired resistance to osimertinib in non–small cell lung cancer.

May 05, 2020

Terence M. Williams, MD, PhD, discusses research examining a serum biomarker, neutrophil-to-lymphocyte ratio, in non–small cell lung cancer.

May 01, 2020

Hui-Zi Chen, MD, PhD, discusses the use of rapid research autopsy in metastatic ultra-hypermutated interdigitating dendritic cell sarcoma, an extremely rare cancer of dendritic origin that lacks a standardized treatment approach.

April 23, 2020

We recently traveled to Columbus, Ohio for a State of the Science Summit™ on Ovarian Cancer, which featured insights from The Ohio State University Comprehensive Cancer Center–James faculty.

April 22, 2020

David O'Malley, MD, discusses antitumor activity with veliparib in combination with chemotherapy in patients with high grade serous ovarian cancer.

April 15, 2020

Comprehensive genomic profiling can be successfully performed in the majority of patients with sarcoma, depending on the tumor location and tissue subtype, which can impact treatment decisions and patient outcomes.

April 09, 2020

Jennifer Woyach, MD, discusses the utility of time-limited therapies in chronic lymphocytic leukemia.

April 08, 2020

David O’Malley, MD, discusses the current state of immunotherapy in ovarian cancer.

April 08, 2020

Casey M. Cosgrove, MD, discusses the utilization of PARP inhibition in ovarian cancer.